WELCOME

MoonLake Immunotherapeutics

Next-level therapies to elevate care

INTRODUCTION

Life-changing therapies for people living with serious inflammatory diseases

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of Sonelokimab, a novel investigational Nanobody® for the treatment of inflammation, to elevate outcomes for patients.

WHAT’S GOING ON

MoonLake news

05/22
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
READ MORE +
04/22
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp
READ MORE +
03/22
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
READ MORE +
08/21
MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors
READ MORE +
ABOUT US

We go
beyond

We go beyond by bringing unrivalled expertise and experience to innovate the way new treatments are developed for inflammatory diseases.
READ MORE +
SCIENCE

We do stellar science

We apply stellar science, sponsoring innovative research work and clinical trials globally, to target inflammatory diseases with a major unmet need where Sonelokimab has the potential to transform patient outcomes.
READ MORE +
INVESTOR RELATIONS

We unlock
value

We are unlocking the value of Sonelokimab with our ambitious Phase 2 program across lead indications for hidradenitis suppurativa, psoriatic arthritis and ankylosing spondylitis (or r-axSpA).
READ MORE +